ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.1840G>T (p.Gly614Ter)

dbSNP: rs1380847972
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Color Diagnostics, LLC DBA Color Health RCV001188274 SCV001355296 pathogenic Hereditary cancer-predisposing syndrome 2019-10-21 criteria provided, single submitter clinical testing This variant changes 1 nucleotide in exon 12 of the MSH2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in an individual affected with colon cancer whose tumor showed microsatellite instability and loss of MSH2 by immunohistochemistry (PMID: 30693488). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease. Based on the available evidence, this variant is classified as Pathogenic.
Ambry Genetics RCV001188274 SCV002717039 pathogenic Hereditary cancer-predisposing syndrome 2021-06-04 criteria provided, single submitter clinical testing The p.G614* pathogenic mutation (also known as c.1840G>T), located in coding exon 12 of the MSH2 gene, results from a G to T substitution at nucleotide position 1840. This changes the amino acid from a glycine to a stop codon within coding exon 12. This mutation has been reported in a 46 year old individual diagnosed with MSI colorectal cancer that exhibited loss of MSH2 and MSH6 proteins on immunohistochemistry (Antelo M et al. Int J Cancer, 2019 08;145:705-713). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV002560014 SCV002966438 pathogenic Hereditary nonpolyposis colorectal neoplasms 2022-03-20 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 925991). This premature translational stop signal has been observed in individual(s) with colorectal cancer (PMID: 30693488). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gly614*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816).
Myriad Genetics, Inc. RCV003449614 SCV004186945 pathogenic Lynch syndrome 1 2023-08-03 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.